comparemela.com

Latest Breaking News On - Clinical program update - Page 1 : comparemela.com

Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab in Patients with Squamous Cell Cancer of the Head and Neck

CAMBRIDGE - Infinity Pharmaceuticals, Inc. , a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced.

United kingdomEzra cohenRobert ilariaMelissa hackelInfinity pharmaceuticals incMorrow sodaliClinical programPharma incInfinity pharmaceuticalsInstitutional shareholder services incLewis co glassDrug administrationChief medicalInfinity chief medical officerInfinity mergerClinical program update

Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with Squamous Cell Cancer of the Head and Neck (SCCHN)

CAMBRIDGE, Mass. (BUSINESS WIRE) Jul 10, 2023

United statesUnited kingdomEzra cohenRobert ilariaMelissa hackelExchange commissionClinical program updateInstitutional shareholder services incMorrow sodaliDrug administrationInfinity pharmaceuticalsPharma incInfinity pharmaceuticals incLewis co glassChief medicalInfinity chief medical officer robert ilaria

vimarsana © 2020. All Rights Reserved.